NASDAQ: QURE: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE)

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for misleading investors regarding its gene therapy drug AMT-130 during the specified Class Period [2][4][5]. Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, particularly Huntington's disease (HD) [4]. - The company's leading drug candidate is AMT-130, aimed at slowing the progression of HD [4]. Lawsuit Details - The lawsuit, titled Scocco v. uniQure N.V., was filed in the United States District Court for the Southern District of New York [2]. - The Class Period for the lawsuit is defined as September 24, 2025, to October 31, 2025 [7]. - Investors who purchased shares during this period may seek to serve as lead plaintiffs by April 13, 2026 [3][9]. Allegations - The complaint alleges that uniQure made materially false and misleading statements regarding its Phase I/II clinical trials and the timeline for its Biologics License Application (BLA) submission to the FDA [5]. - Specific allegations include: 1. The design of the Pivotal Study was not fully approved by the FDA [5]. 2. The likelihood of needing to delay the BLA timeline was downplayed [5]. 3. Statements about the company's business and prospects lacked a reasonable basis [5]. Impact on Share Price - On November 3, 2025, uniQure's share price dropped by $33.40, or over 49%, from $67.69 to $34.29 following the revelation that the FDA did not agree with the adequacy of the data for BLA submission [6][8].